Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis

Divyanshu Dubey, Christopher A. Cano, Olaf Stüve

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: As of April 2015, 13 disease modifying therapies (DMTs) have been approved by the Food and Drug Administration. The older agents continue to be utilized across the globe, especially in developing countries where many newer DMTs are still not available. Even though first generation DMTs have modest efficacy they have long term safety profile, and are considered safer than the second generation DMTs. RECENT FINDINGS: A PEGylated interferon beta-1a preparation that is administered subcutaneously every 2 weeks was also recently approved. Less frequent administration potentially reduced administration associated side effects and may improve adherence and compliance. The polyethylene glycol is also thought to make the drug less immunogenic. Glatopa (a glatiramer acetate bioequivalent), now represents the first available generic alternative of a DMT for multiple sclerosis. Its dosing, route of administration, and side effects are the same as for Copaxone. SUMMARY: In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions.

Original languageEnglish (US)
JournalCurrent Opinion in Neurology
DOIs
StateAccepted/In press - Mar 31 2016

Fingerprint

Cohort Effect
Multiple Sclerosis
Therapeutics
United States Food and Drug Administration
Developing Countries
Compliance
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{0cb3bbe4f4bc4b4f85c7f112b0e0ba41,
title = "Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis",
abstract = "PURPOSE OF REVIEW: As of April 2015, 13 disease modifying therapies (DMTs) have been approved by the Food and Drug Administration. The older agents continue to be utilized across the globe, especially in developing countries where many newer DMTs are still not available. Even though first generation DMTs have modest efficacy they have long term safety profile, and are considered safer than the second generation DMTs. RECENT FINDINGS: A PEGylated interferon beta-1a preparation that is administered subcutaneously every 2 weeks was also recently approved. Less frequent administration potentially reduced administration associated side effects and may improve adherence and compliance. The polyethylene glycol is also thought to make the drug less immunogenic. Glatopa (a glatiramer acetate bioequivalent), now represents the first available generic alternative of a DMT for multiple sclerosis. Its dosing, route of administration, and side effects are the same as for Copaxone. SUMMARY: In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions.",
author = "Divyanshu Dubey and Cano, {Christopher A.} and Olaf St{\"u}ve",
year = "2016",
month = "3",
day = "31",
doi = "10.1097/WCO.0000000000000320",
language = "English (US)",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis

AU - Dubey, Divyanshu

AU - Cano, Christopher A.

AU - Stüve, Olaf

PY - 2016/3/31

Y1 - 2016/3/31

N2 - PURPOSE OF REVIEW: As of April 2015, 13 disease modifying therapies (DMTs) have been approved by the Food and Drug Administration. The older agents continue to be utilized across the globe, especially in developing countries where many newer DMTs are still not available. Even though first generation DMTs have modest efficacy they have long term safety profile, and are considered safer than the second generation DMTs. RECENT FINDINGS: A PEGylated interferon beta-1a preparation that is administered subcutaneously every 2 weeks was also recently approved. Less frequent administration potentially reduced administration associated side effects and may improve adherence and compliance. The polyethylene glycol is also thought to make the drug less immunogenic. Glatopa (a glatiramer acetate bioequivalent), now represents the first available generic alternative of a DMT for multiple sclerosis. Its dosing, route of administration, and side effects are the same as for Copaxone. SUMMARY: In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions.

AB - PURPOSE OF REVIEW: As of April 2015, 13 disease modifying therapies (DMTs) have been approved by the Food and Drug Administration. The older agents continue to be utilized across the globe, especially in developing countries where many newer DMTs are still not available. Even though first generation DMTs have modest efficacy they have long term safety profile, and are considered safer than the second generation DMTs. RECENT FINDINGS: A PEGylated interferon beta-1a preparation that is administered subcutaneously every 2 weeks was also recently approved. Less frequent administration potentially reduced administration associated side effects and may improve adherence and compliance. The polyethylene glycol is also thought to make the drug less immunogenic. Glatopa (a glatiramer acetate bioequivalent), now represents the first available generic alternative of a DMT for multiple sclerosis. Its dosing, route of administration, and side effects are the same as for Copaxone. SUMMARY: In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions.

UR - http://www.scopus.com/inward/record.url?scp=84962071052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962071052&partnerID=8YFLogxK

U2 - 10.1097/WCO.0000000000000320

DO - 10.1097/WCO.0000000000000320

M3 - Article

C2 - 27035896

AN - SCOPUS:84962071052

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

ER -